XenTech

XenTech isFrench non-clinical CRO specializing in oncology. We have particular strengths in PDX models using patient-derived tumor tissues, and we provide contract services at our own facilities for in vivo efficacy evaluation, PK/PD, and biomarker discovery, among others.

Features of XenTech's non-clinical contract testing services

Evaluate candidate compounds using patient-derived PDX models

XenTech isPDX model in which patient-derived tumor tissue is transplanted into immunodeficient miceWe are building a drug discovery platform centered on , capable of evaluating drug efficacy using a diverse range of tumor models, focusing mainly on solid tumors such as breast, colorectal, and lung cancer. Because models can be selected taking into account reactivity to standard treatments and molecular characteristics, the effects of candidate compounds can be examined in an environment closer to the clinical setting. Backed by a research foundation with Institut Curie—which has been involved in PDX research since 1989—we have a track record of over 2,500 in vivo studies.

Evaluate not only drug efficacy but also PK/PD, pathology, and biomarkers

It is possible to combine in vivo efficacy studies with multiple analytical technologies.This is also a feature. In efficacy evaluations, blood analysis, IHC, molecular profiling, etc., can be added, and blood and tissue sampling for PK/PD is also supported. In addition, by comparing PDX drug responses with molecular information such as genetic mutations, copy numbers, and gene/protein expression, biomarkers related to treatment response and resistance can be explored. We support translational research, ranging from confirming the efficacy of candidate compounds to investigating the target patient population.

Flexible support from standard models to custom models

At XenTech,Configure PDX models and study designs to fit research objectives.It is possible. We provide models that replicate metastasis, models to evaluate residual tumor cells after chemotherapy, and PDXs with acquired resistance to specific treatments. In addition, we support orthotopic transplantation models, bioluminescent PDXs, syngeneic models, and humanized models. The facility is an ISO 9001-certified vivarium, and we also undertake custom studies tailored to your research objectives. Please note that since GLP certification cannot be confirmed on the official website, prior confirmation is necessary if GLP-compliant studies are required.

An example of disease models owned by XenTech

At XenTech,PDX models derived from treatment-resistant cancer patientsWe are deploying the MATCH-R collection, which includes [insert term], models generated from tumors of patients who experienced disease progression after an initial response to treatment. These can be used to analyze mechanisms of acquired resistance and explore new therapeutic approaches. For breast cancer, it covers multiple subtypes such as triple-negative.

XenTech non-clinical study cases

Comparative evaluation of candidate drugs using 21 colorectal cancer PDX models

XenTech isPreclinical phase II-like trial using 21 colorectal cancer PDX modelsWe are publishing research results evaluating multiple standard therapies as single agents or in combination, comparing drug reactivity across tumor models. By reproducing the biological diversity of tumors found in patient populations using PDX panels, this is utilized in research examining the efficacy of candidate drugs and the selection of appropriate models.

XenTech Corporate Information